CureVac CEO on IPO Pricing, Covid-19 Vaccine, Partners

The transcript discusses stock pricing and market demand, highlighting a significant spread in stock opening prices. It covers a partnership with GSK for vaccine development, focusing on mRNA technology and clinical trials. The conversation also addresses funding, government involvement, and the global race to develop a COVID-19 vaccine, emphasizing the importance of safety, efficacy, and manufacturing capabilities.

What was the initial stock price mentioned, and what was the potential opening price discussed?

• Initial price $25, potential opening $55

• Initial price $30, potential opening $70

• Initial price $20, potential opening $60

• Initial price $16, potential opening $50

Which company did the speaker mention partnering with for vaccine development?

• Johnson & Johnson

• Moderna

• GlaxoSmithKline (GSK)

• Pfizer

What technology is being used to deliver the vaccine's message to the body?

• DNA

• Lipid

• Protein

• RNA

What is the estimated cost mentioned for the accelerated vaccine development?

• A significant 5-digit million amount

• A significant 3-digit million amount

• A significant 4-digit million amount

• A significant 2-digit million amount

Who are considered the primary customers for the vaccines according to the speaker?

• Private hospitals

• Insurance companies

• Governments

• Pharmaceutical companies

What is the main competition in the vaccine development race according to the speaker?

• Manufacturing companies

• Other vaccine producers

• The virus itself

• Regulatory bodies

What is a key factor in determining the success of a vaccine according to the speaker?

• Being the most advertised

• Being the first to market

• Having the lowest cost

• Generating sufficient protection